Dihydrotestosterone (DHT), also known as 5α-Dihydrotestosterone or Androstanolone, is an endogenous androgen sex steroid and hormone. It is primarily produced in the gonads and adrenal glands through the conversion of testosterone by the enzyme 5α-reductase. DHT belongs to the class of androgens, which are a subset of steroid hormones. It is a potent androgen with a significant role in the development of male characteristics and is also present in females in smaller amounts. Researchers have found that DHT plays a crucial role in the development of male primary and secondary sexual characteristics, such as facial hair, deepening of the voice, and muscle growth. It is also involved in the pathophysiology of conditions like androgenetic alopecia and benign prostatic hyperplasia. Research areas include its role in prostate health, hair loss, and its potential therapeutic applications in hormone replacement therapy. DHT exerts its effects by binding to androgen receptors, which then translocate to the cell nucleus and modulate the expression of specific genes. This action initiates a cascade of biological processes that lead to the development of male characteristics and other androgenic effects. The pharmacokinetic properties of DHT include a circulating half-life of approximately 70 minutes. It is metabolized primarily in the liver and excreted in urine. The bioavailability of DHT varies depending on the route of administration, with oral bioavailability being poor due to first-pass metabolism. Clinically, DHT is used in certain hormone replacement therapies and has been studied for its effects on conditions like hypogonadism. Its use is regulated, and it is classified as a controlled substance in many countries due to its potent androgenic effects and potential for misuse.